Search results

Filter (9 in use)

Type 1 selected

Status 2 selected

Last updated

Guidance programme 6 selected

1725 results

Date Relevance

  5. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer in adults. This involves using

    Interventional procedures guidance
    Published
    View recommendations

  6. Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy (IPG615)

    Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

    Interventional procedures guidance
    Published
    View recommendations

  7. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

    Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults

    Technology appraisal guidance
    Published
    View recommendations

  10. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG611)

    Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults

    Interventional procedures guidance
    Published
    View recommendations

  11. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)

    Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults

    Interventional procedures guidance
    Published
    View recommendations

  12. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated locally advanced or metastatic urothelial carcinoma in adults

    Technology appraisal guidance
    Published
    View recommendations

  16. Stop smoking interventions and services (NG92)

    This guideline covers stop smoking interventions and services delivered in primary care and community settings for everyone over the age of 12. It aims to ensure that everyone who smokes is advised and encouraged to stop and given the support they need. It emphasises the importance of targeting vulnerable groups who find smoking cessation hard or who smoke a lot.

    NICE guideline
    Published
    View recommendations

  17. Otitis media (acute): antimicrobial prescribing (NG91)

    This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

    Antimicrobial prescribing guideline
    Published
    View recommendations

  18. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

    Technology appraisal guidance
    Published
    View recommendations

  20. Physical activity and the environment (NG90)

    This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

    NICE guideline
    Published
    View recommendations

  27. Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA508)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

    Technology appraisal guidance
    Published
    View recommendations

  28. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been

    Technology appraisal guidance
    Published
    View recommendations

  29. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson’s disease in adults

    Interventional procedures guidance
    Published
    View recommendations

  30. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

    Technology appraisal guidance
    Published
    View recommendations

  32. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

    Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

    Highly specialised technologies guidance
    Published

  33. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

    Evidence-based recommendations on ixazomib (Ninlaro), with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults

    Technology appraisal guidance
    Published
    View recommendations

  35. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

    Technology appraisal guidance
    Last updated
    View recommendations

  36. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

    Technology appraisal guidance
    Last updated
    View recommendations

  38. Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

    Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

    Technology appraisal guidance
    Published
    View recommendations

  39. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults

    Technology appraisal guidance
    Published
    View recommendations

  41. Sore throat (acute): antimicrobial prescribing (NG84)

    This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

    Antimicrobial prescribing guideline
    Published
    View recommendations

  42. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

    Technology appraisal guidance
    Published
    View recommendations

  44. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

    Technology appraisal guidance
    Published
    View recommendations

  46. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (IPG603)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a

    Interventional procedures guidance
    Published
    View recommendations

  47. Endobronchial valve insertion to reduce lung volume in emphysema (IPG600)

    Evidence-based recommendations on endobronchial valve insertion to reduce lung volume in emphysema. This involves placing small one-way valves in some airways

    Interventional procedures guidance
    Published
    View recommendations

  48. Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (IPG601)

    Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to

    Interventional procedures guidance
    Published
    View recommendations

  49. Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure (IPG602)

    Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure

    Interventional procedures guidance
    Published
    View recommendations

  50. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

    Technology appraisal guidance
    Published
    View recommendations